We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · February 07, 2021

Effect of Tocilizumab on Clinical Outcomes at 15 Days in Patients With Severe or Critical COVID-19

BMJ : British Medical Journal

 

Additional Info

Disclosure statements are available on the authors' profiles:

BMJ : British Medical Journal
Effect of Tocilizumab on Clinical Outcomes at 15 Days in Patients With Severe or Critical Coronavirus Disease 2019: Randomised Controlled Trial
BMJ 2021 Jan 20;372(xx)n84, VC Veiga, JAGG Prats, DLC Farias, RG Rosa, LK Dourado, FG Zampieri, FR Machado, RD Lopes, O Berwanger, LCP Azevedo, Á Avezum, TC Lisboa, SSO Rojas, JC Coelho, RT Leite, JC Carvalho, LEC Andrade, AF Sandes, MCT Pintão, CG Castro, SV Santos, TML de Almeida, AN Costa, OCE Gebara, FGR de Freitas, ES Pacheco, DJB Machado, J Martin, FG Conceição, SRR Siqueira, LP Damiani, LM Ishihara, D Schneider, D de Souza, AB Cavalcanti, P Scheinberg

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading